• Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic

    Wednesday August 10th 2022

  • Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®

    Monday August 8th 2022

  • S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities

    Tuesday August 2nd 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022

  • NEXTSTELLIS® oral contraceptive now available in Australia

    Tuesday July 26th 2022

  • Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225

    Tuesday July 26th 2022

  • Sequana Medical secures EUR 10 million loan facility with Kreos Capital

    Wednesday July 20th 2022

  • Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study and reports disease-modifying profile for Short Term DSR

    Tuesday July 19th 2022

  • Your news here?

  • Agomab raises additional $40.5 million through Series B extension bringing total amount to $114 million

    Wednesday July 13th 2022

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    Tuesday July 5th 2022

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody® drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

Strategic Partners